ID   CP26B_HUMAN             Reviewed;         512 AA.
AC   Q9NR63; B2R8M7; B7Z2K6; B7Z2P4; B7Z3B8; E4W5W7; Q32MC0; Q53TW1;
AC   Q9NP41;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 146.
DE   RecName: Full=Cytochrome P450 26B1;
DE            EC=1.14.13.- {ECO:0000269|PubMed:10823918, ECO:0000269|PubMed:26937021};
DE   AltName: Full=Cytochrome P450 26A2;
DE   AltName: Full=Cytochrome P450 retinoic acid-inactivating 2;
DE            Short=Cytochrome P450RAI-2;
DE   AltName: Full=Retinoic acid-metabolizing cytochrome;
GN   Name=CYP26B1; Synonyms=CYP26A2, P450RAI2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   TISSUE SPECIFICITY, AND INDUCTION.
RC   TISSUE=Retina;
RX   PubMed=10823918; DOI=10.1073/pnas.120161397;
RA   White J.A., Ramshaw H., Taimi M., Stangle W., Zhang A., Everingham S.,
RA   Creighton S., Tam S.-P., Jones G., Petkovich M.;
RT   "Identification of the human cytochrome P450, P450RAI-2, which is
RT   predominantly expressed in the adult cerebellum and is responsible for
RT   all-trans-retinoic acid metabolism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:6403-6408(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT SER-264.
RC   TISSUE=Vascular smooth muscle;
RA   Savenstrand H., Kumawat A., Karlsson M., Eriksson L.A., Sirsjo A.,
RA   Strid A.;
RT   "A spliced version of the human cytochrome P450 26B1 has an
RT   alternative function in retinoic acid metabolism.";
RL   Submitted (NOV-2008) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND
RP   VARIANT SER-264.
RC   TISSUE=Brain, Cerebellum, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-181; VAL-185;
RP   HIS-191; ASN-227; SER-264; LYS-380; GLY-420; CYS-473 AND ILE-479.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND VARIANTS RHFCA PRO-146 AND LEU-363.
RX   PubMed=22019272; DOI=10.1016/j.ajhg.2011.09.015;
RA   Laue K., Pogoda H.M., Daniel P.B., van Haeringen A., Alanay Y.,
RA   von Ameln S., Rachwalski M., Morgan T., Gray M.J., Breuning M.H.,
RA   Sawyer G.M., Sutherland-Smith A.J., Nikkels P.G., Kubisch C.,
RA   Bloch W., Wollnik B., Hammerschmidt M., Robertson S.P.;
RT   "Craniosynostosis and multiple skeletal anomalies in humans and
RT   zebrafish result from a defect in the localized degradation of
RT   retinoic acid.";
RL   Am. J. Hum. Genet. 89:595-606(2011).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   VARIANT ARG-64.
RX   PubMed=26937021; DOI=10.1124/jpet.116.232637;
RA   Foti R.S., Isoherranen N., Zelter A., Dickmann L.J., Buttrick B.R.,
RA   Diaz P., Douguet D.;
RT   "Identification of tazarotenic acid as the first xenobiotic substrate
RT   of human retinoic acid hydroxylase CYP26A1 and CYP26B1.";
RL   J. Pharmacol. Exp. Ther. 357:281-292(2016).
CC   -!- FUNCTION: Involved in the metabolism of retinoic acid (RA),
CC       rendering this classical morphogen inactive through oxidation.
CC       Involved in the specific inactivation of all-trans-retinoic acid
CC       (all-trans-RA), with a preference for the following substrates:
CC       all-trans-RA > 9-cis-RA > 13-cis-RA. Generates several
CC       hydroxylated forms of RA, including 4-OH-RA, 4-oxo-RA, and 18-OH-
CC       RA. Essential for postnatal survival. Plays a central role in germ
CC       cell development: acts by degrading RA in the developing testis,
CC       preventing STRA8 expression, thereby leading to delay of meiosis.
CC       Required for the maintenance of the undifferentiated state of male
CC       germ cells during embryonic development in Sertoli cells, inducing
CC       arrest in G0 phase of the cell cycle and preventing meiotic entry.
CC       Plays a role in skeletal development, both at the level of
CC       patterning and in the ossification of bone and the establishment
CC       of some synovial joints. {ECO:0000269|PubMed:10823918,
CC       ECO:0000269|PubMed:22019272}.
CC   -!- FUNCTION: Has also a significant activity in oxidation of
CC       tazarotenic acid and may therefore metabolize that xenobiotic in
CC       vivo. {ECO:0000269|PubMed:26937021}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413; Evidence={ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.01 uM for tazarotenic acid (measured in vitro by the
CC         production of tazarotenic acid-sulfoxide)
CC         {ECO:0000269|PubMed:26937021};
CC         KM=0.56 uM for tazarotenic acid (measured in vitro by the
CC         production of hydroxytazarotenic acid production)
CC         {ECO:0000269|PubMed:26937021};
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250}; Peripheral membrane protein {ECO:0000250}.
CC       Microsome membrane {ECO:0000250}; Peripheral membrane protein
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9NR63-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NR63-2; Sequence=VSP_042968;
CC       Name=3;
CC         IsoId=Q9NR63-3; Sequence=VSP_042967;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, particularly in the
CC       cerebellum and pons. {ECO:0000269|PubMed:10823918}.
CC   -!- INDUCTION: By retinoic acid. {ECO:0000269|PubMed:10823918}.
CC   -!- DISEASE: Radiohumeral fusions with other skeletal and craniofacial
CC       anomalies (RHFCA) [MIM:614416]: A disease characterized by
CC       craniofacial malformations, occipital encephalocele, radiohumeral
CC       fusions, oligodactyly, advanced osseous maturation, and calvarial
CC       mineralization defects. {ECO:0000269|PubMed:22019272}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAH12154.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/cyp26b1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF252297; AAF76003.1; -; mRNA.
DR   EMBL; FJ467289; ACR19332.1; -; mRNA.
DR   EMBL; AK294814; BAH11892.1; -; mRNA.
DR   EMBL; AK294933; BAH11930.1; -; mRNA.
DR   EMBL; AK295683; BAH12154.1; ALT_INIT; mRNA.
DR   EMBL; AK313433; BAG36224.1; -; mRNA.
DR   EMBL; AC007002; AAY14690.1; -; Genomic_DNA.
DR   EMBL; BC069443; AAH69443.1; -; mRNA.
DR   EMBL; BC109205; AAI09206.1; -; mRNA.
DR   CCDS; CCDS1919.1; -. [Q9NR63-1]
DR   CCDS; CCDS62934.1; -. [Q9NR63-2]
DR   RefSeq; NP_001264671.1; NM_001277742.1. [Q9NR63-2]
DR   RefSeq; NP_063938.1; NM_019885.3. [Q9NR63-1]
DR   UniGene; Hs.91546; -.
DR   ProteinModelPortal; Q9NR63; -.
DR   SMR; Q9NR63; -.
DR   BioGrid; 121153; 2.
DR   STRING; 9606.ENSP00000001146; -.
DR   iPTMnet; Q9NR63; -.
DR   PhosphoSitePlus; Q9NR63; -.
DR   DMDM; 20137526; -.
DR   MaxQB; Q9NR63; -.
DR   PaxDb; Q9NR63; -.
DR   PeptideAtlas; Q9NR63; -.
DR   PRIDE; Q9NR63; -.
DR   Ensembl; ENST00000001146; ENSP00000001146; ENSG00000003137. [Q9NR63-1]
DR   Ensembl; ENST00000546307; ENSP00000443304; ENSG00000003137. [Q9NR63-2]
DR   GeneID; 56603; -.
DR   KEGG; hsa:56603; -.
DR   UCSC; uc002sih.3; human. [Q9NR63-1]
DR   CTD; 56603; -.
DR   DisGeNET; 56603; -.
DR   GeneCards; CYP26B1; -.
DR   HGNC; HGNC:20581; CYP26B1.
DR   HPA; HPA012567; -.
DR   MalaCards; CYP26B1; -.
DR   MIM; 605207; gene.
DR   MIM; 614416; phenotype.
DR   neXtProt; NX_Q9NR63; -.
DR   OpenTargets; ENSG00000003137; -.
DR   Orphanet; 293925; Lethal occipital encephalocele-skeletal dysplasia syndrome.
DR   PharmGKB; PA134879191; -.
DR   eggNOG; KOG0157; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00800000124060; -.
DR   HOGENOM; HOG000220829; -.
DR   HOVERGEN; HBG051099; -.
DR   InParanoid; Q9NR63; -.
DR   KO; K12664; -.
DR   OMA; GGGCPCE; -.
DR   OrthoDB; EOG091G0K6Z; -.
DR   PhylomeDB; Q9NR63; -.
DR   TreeFam; TF105093; -.
DR   Reactome; R-HSA-211916; Vitamins.
DR   Reactome; R-HSA-5365859; RA biosynthesis pathway.
DR   GeneWiki; CYP26B1; -.
DR   GenomeRNAi; 56603; -.
DR   PRO; PR:Q9NR63; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000003137; -.
DR   CleanEx; HS_CYP26B1; -.
DR   ExpressionAtlas; Q9NR63; baseline and differential.
DR   Genevisible; Q9NR63; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0020037; F:heme binding; NAS:BHF-UCL.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0016709; F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen; IDA:UniProtKB.
DR   GO; GO:0008401; F:retinoic acid 4-hydroxylase activity; IDA:BHF-UCL.
DR   GO; GO:0001972; F:retinoic acid binding; IDA:BHF-UCL.
DR   GO; GO:0060349; P:bone morphogenesis; IMP:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; ISS:BHF-UCL.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0070268; P:cornification; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0061436; P:establishment of skin barrier; IEA:Ensembl.
DR   GO; GO:0001768; P:establishment of T cell polarity; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0007140; P:male meiosis; ISS:BHF-UCL.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:2001037; P:positive regulation of tongue muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0009954; P:proximal/distal pattern formation; ISS:BHF-UCL.
DR   GO; GO:0045580; P:regulation of T cell differentiation; IEA:Ensembl.
DR   GO; GO:0034653; P:retinoic acid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0048384; P:retinoic acid receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; ISS:BHF-UCL.
DR   GO; GO:0016125; P:sterol metabolic process; IBA:GO_Central.
DR   GO; GO:0043587; P:tongue morphogenesis; IEA:Ensembl.
DR   GO; GO:0006766; P:vitamin metabolic process; TAS:Reactome.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IDA:UniProtKB.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002403; Cyt_P450_E_grp-IV.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00465; EP450IV.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Craniosynostosis;
KW   Disease mutation; Endoplasmic reticulum; Heme; Iron; Membrane;
KW   Metal-binding; Microsome; Monooxygenase; Oxidoreductase; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    512       Cytochrome P450 26B1.
FT                                /FTId=PRO_0000051985.
FT   METAL       441    441       Iron (heme axial ligand). {ECO:0000255}.
FT   VAR_SEQ       1     67       MLFEGLDLVSALATLAACLVSVTLLLAVSQQLWQLRWAATR
FT                                DKSCKLPIPKGSMGFPLIGETGHWLL -> MKNKTCVLVCV
FT                                SVFGGERGQVTVPRVGVRRPSLAGPLQKCTLRETRVWLP
FT                                (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042967.
FT   VAR_SEQ      69    143       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_042968.
FT   VARIANT      64     64       H -> R. {ECO:0000269|PubMed:26937021}.
FT                                /FTId=VAR_075982.
FT   VARIANT     146    146       S -> P (in RHFCA; dbSNP:rs281875232).
FT                                {ECO:0000269|PubMed:22019272}.
FT                                /FTId=VAR_067923.
FT   VARIANT     181    181       V -> M (in dbSNP:rs142999899).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038722.
FT   VARIANT     185    185       A -> V (in dbSNP:rs765423228).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038723.
FT   VARIANT     191    191       R -> H (in dbSNP:rs76025186).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038724.
FT   VARIANT     227    227       D -> N (in dbSNP:rs143738797).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038725.
FT   VARIANT     264    264       L -> S (in dbSNP:rs2241057).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.2, ECO:0000269|Ref.4}.
FT                                /FTId=VAR_024383.
FT   VARIANT     363    363       R -> L (in RHFCA; dbSNP:rs281875231).
FT                                {ECO:0000269|PubMed:22019272}.
FT                                /FTId=VAR_067924.
FT   VARIANT     380    380       E -> K (in dbSNP:rs2286965).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038726.
FT   VARIANT     420    420       A -> G (in dbSNP:rs7568553).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038727.
FT   VARIANT     473    473       R -> C (in dbSNP:rs61751056).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038728.
FT   VARIANT     479    479       V -> I (in dbSNP:rs148075682).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_038729.
FT   CONFLICT    265    265       D -> G (in Ref. 3; BAH11930).
FT                                {ECO:0000305}.
SQ   SEQUENCE   512 AA;  57513 MW;  A06D1D9944E6726F CRC64;
     MLFEGLDLVS ALATLAACLV SVTLLLAVSQ QLWQLRWAAT RDKSCKLPIP KGSMGFPLIG
     ETGHWLLQGS GFQSSRREKY GNVFKTHLLG RPLIRVTGAE NVRKILMGEH HLVSTEWPRS
     TRMLLGPNTV SNSIGDIHRN KRKVFSKIFS HEALESYLPK IQLVIQDTLR AWSSHPEAIN
     VYQEAQKLTF RMAIRVLLGF SIPEEDLGHL FEVYQQFVDN VFSLPVDLPF SGYRRGIQAR
     QILQKGLEKA IREKLQCTQG KDYLDALDLL IESSKEHGKE MTMQELKDGT LELIFAAYAT
     TASASTSLIM QLLKHPTVLE KLRDELRAHG ILHSGGCPCE GTLRLDTLSG LRYLDCVIKE
     VMRLFTPISG GYRTVLQTFE LDGFQIPKGW SVMYSIRDTH DTAPVFKDVN VFDPDRFSQA
     RSEDKDGRFH YLPFGGGVRT CLGKHLAKLF LKVLAVELAS TSRFELATRT FPRITLVPVL
     HPVDGLSVKF FGLDSNQNEI LPETEAMLSA TV
//
